Idiopathic Pulmonary Fibrosis Susceptibility Identified Via Genomic Markers
Altered expression of 14 genes in adults was associated with idiopathic pulmonary fibrosis susceptibility.
Restrictive Lung Disease
Chronic Viral Infection May Increase Idiopathic Pulmonary Fibrosis Risk
Persistent or chronic, but not acute, viral infections significantly increase the risk of developing idiopathic pulmonary fibrosis.
Greater Circulating Adipokines May Play a Role in Early ILD Pathogenesis
Higher adiponectin levels are associated with lower high attenuation areas, a computed tomography-based measure of subclinical interstitial lung disease.
Obesity Linked to Underutilization of Low Tidal Volume Ventilation in ARDS
ARDS was underrecognized in the study population across all body mass indexesBMIs, but this underrecognition did not explain why patients with class 3 obesity were more likely to meet ARDS criteria but not receive low tidal volume ventilation.
Combination Metformin and Low-Dose Nintedanib Reduces Pulmonary Fibrosis
Metformin was effective in reducing pulmonary fibrosis in human IPF fibroblasts and when used in combination with low-dose nintedanib, demonstrated a synergistic, antifibrotic effect.
Statins Taken Before Septic Shock May Reduce ARDS Risk
Statin therapy before septic shock may decrease the risk for acute respiratory distress syndrome.
ILD Associated With More Muscle Mass, Less Bone Density Loss
Researchers of the study aimed to determine the differences in muscle area and bone density in patients with end-stage lung disease.
Nintedanib Granted Breakthrough Therapy for Progressive Fibrosing Interstitial Lung Disease
The FDA has granted Breakthrough Therapy designation to nintedanib for the treatment of chronic fibrosing ILDs with a progressive phenotype.
Is Prone Ventilation Limited for Patients With Mild or Moderate ARDS?
Researchers question previous recommendations that demonstrated that prone ventilation reduced mortality in patients with acute respiratory distress syndrome.
Pirfenidone May Benefit Unclassifiable Progressive Fibrosing Interstitial Lung Disease
Although the planned statistical model could not be applied to primary end point data, key secondary end point analysis suggested that patients with progressive fibrosing unclassifiable interstitial lung disease could benefit from pirfenidone.
Next post in Restrictive Lung Disease
